Also known as KEYTRUDA and KEYTRUDA®.
First interim IDMC readout from LiGeR‑HN1 shows a 50% reduction in risk of death and a >3‑fold increase in objective response for the combination versus pembrolizumab alone.
Combination therapy produced 28.2‑month median OS, 63% ORR and 9.0‑month mPFS in first‑line PD‑L1+ recurrent/metastatic head and neck cancer, with responses across HPV status.
Phase 3 KEYNOTE‑C93: pembrolizumab alone extended median PFS to 38.2 vs 8.4 months versus platinum doublet; results presented at ESMO and published in The Lancet.
Cohort 5 reported 77% confirmed ORR (14% CR) in non‑HPV HNSCC with subcutaneous amivantamab + pembrolizumab and carboplatin; median follow‑up 10.6 months; safety consistent with known profiles.
Durable PFS and DOR not reached with immunotherapy combo; chemoimmunotherapy combo showed 62% ORR and 14.5‑month median DOR in first-line KRAS G12C NSCLC.
Phase III Krascendo 1: divarasib reduced risk of progression/death by 42% and risk of death by 44%; median OS ~17.7 vs 12.0 months; ORR 58% vs 32%; manageable safety.
New clinical results include first-in-human data for oral RIPTAC JNJ-6143 in mCRPC, late-breaking PROTEUS Phase 3 prostate results, and expanded RYBREVANT FASPRO datasets across lung and head & neck cancers.
Intismeran plus pembrolizumab cut risk of recurrence or death 42% overall and 58% after six months; distant‑metastasis‑free survival also improved; safety profile consistent.
EU clears first PD‑1 inhibitor plus ADC regimen for resectable muscle‑invasive bladder cancer regardless of cisplatin eligibility; phase 3 showed EFS HR 0.53 and OS HR 0.65.
Randomized Phase II will test VVD-214 plus pembrolizumab versus pembrolizumab alone as first‑line treatment for advanced MSI‑high/dMMR colorectal cancer, enrolling ~140 patients.
